Kristen Cunningham Sells 8,901 Shares of Lifevantage (NASDAQ:LFVN) Stock

Lifevantage Corporation (NASDAQ:LFVN) insider Kristen Cunningham sold 8,901 shares of the business’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $6.18, for a total value of $55,008.18. Following the completion of the sale, the insider directly owned 120,162 shares in the company, valued at approximately $742,601.16. This represents a 6.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Kristen Cunningham also recently made the following trade(s):

• On Friday, September 11th, Kristen Cunningham sold 100 shares of Lifevantage stock. The stock was sold at an average price of $6.41, for a total transaction of $641.00.

Lifevantage Trading Up 1.3%

Shares of Lifevantage stock traded up $0.08 during trading on Monday, reaching $6.25. The company’s stock had a trading volume of 41,083 shares, compared to its average volume of 258,840. Lifevantage Corporation has a one year low of $3.90 and a one year high of $11.71. The stock has a market capitalization of $78.31 million, a P/E ratio of 15.62 and a beta of 0.73. The stock has a 50-day moving average price of $6.41 and a two-hundred day moving average price of $5.94.

Lifevantage (NASDAQ:LFVN) last posted its quarterly earnings data on Thursday, August 27th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.01). The firm had revenue of $42.38 million for the quarter, compared to analyst estimates of $44.00 million. Lifevantage had a return on equity of 21.56% and a net margin of 2.78%. As a group, sell-side analysts anticipate that Lifevantage Corporation will post 0.39 EPS for the current fiscal year.

Lifevantage Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Tuesday, September 1st will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Tuesday, September 1st. Lifevantage’s payout ratio is 50.00%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lifevantage in a research note on Friday, August 21st. Lake Street Capital upped their target price on shares of Lifevantage from $5.00 to $6.00 and gave the company a “hold” rating in a research note on Friday, August 28th. Two investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $5.50.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LFVN. Bank of New York Mellon Corp raised its position in shares of Lifevantage by 11.9% in the first quarter. Bank of New York Mellon Corp now owns 33,547 shares of the company’s stock valued at $145,000 after purchasing an additional 3,571 shares during the period. Bank of America Corp DE lifted its position in Lifevantage by 24.3% during the first quarter. Bank of America Corp DE now owns 23,445 shares of the company’s stock worth $101,000 after acquiring an additional 4,586 shares during the last quarter. DGS Capital Management LLC bought a new stake in shares of Lifevantage during the first quarter worth approximately $44,000. Hsbc Holdings PLC acquired a new position in shares of Lifevantage in the first quarter valued at approximately $51,000. Finally, Aristides Capital LLC bought a new position in shares of Lifevantage during the fourth quarter worth approximately $76,000. Institutional investors and hedge funds own 35.32% of the company’s stock.

Lifevantage Company Profile

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.